The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
复制标题
DOI：
10.1371/journal.pone.0126769
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Bodicoat DH
中科院分区：
文献类型：
--
作者：
Potts JE;Gray LJ;Brady EM;Khunti K;Davies MJ;Bodicoat DH
确定胰高血糖素样肽-1受体激动剂与安慰剂和其他抗糖尿病药物相比对超重或肥胖2型糖尿病患者体重减轻的影响。对随机对照试验进行了电子检索，这些试验在平均体重指数≥ 25 kg/m2的2型糖尿病成人患者中比较了临床相关剂量的胰高血糖素样肽-1受体激动剂治疗与对照药物治疗（其他2型糖尿病治疗或安慰剂）。进行了成对荟萃分析和混合治疗比较，以检查胰高血糖素样肽-1受体激动剂和每种对照药物之间6个月时体重变化的差异。在混合处理比较中（27项试验），胰高血糖素样肽-1受体激动剂在体重减轻方面最成功;艾塞那肽2 mg/周：-1.62 kg（95%CrI：-2.95kg，-0.30kg），艾司那肽20μg：-1.37kg（95% CI：-222 kg，-0.52 kg），利拉鲁肽1.2 mg：-1.01 kg（95%CrI：-2.41 kg，0.38 kg）和利拉鲁肽1.8 mg：-1.51 kg（95% CI：-2.67 kg，-0.37 kg）与安慰剂相比。GLP-1受体激动剂之间在体重减轻方面无差异。本综述提供了证据表明，胰高血糖素样肽-1受体激动剂治疗与超重或肥胖2型糖尿病患者的体重减轻相关，评估的不同类型GLP-1受体激动剂之间的体重减轻无差异。
To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus. Electronic searches were conducted for randomised controlled trials that compared a glucagon-like peptide-1 receptor agonist therapy at a clinically relevant dose with a comparator treatment (other type 2 diabetes treatment or placebo) in adults with type 2 diabetes and a mean body mass index ≥ 25kg/m2. Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator. In the mixed treatment comparison (27 trials), the glucagon-like peptide-1 receptor agonists were the most successful in terms of weight loss; exenatide 2mg/week: -1.62kg (95% CrI: -2.95kg, -0.30kg), exenatide 20μg: -1.37kg (95% CI: -222kg, -0.52kg), liraglutide 1.2mg: -1.01kg (95%CrI: -2.41kg, 0.38kg) and liraglutide 1.8mg: -1.51 kg (95% CI: -2.67kg, -0.37kg) compared with placebo. There were no differences between the GLP-1 receptor agonists in terms of weight loss. This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.
登录
查看更多内容
影响因子：
39.2
作者：
Heine, RJ;Van Gaal, LF;Brodows, RG
通讯作者：
Brodows, RG
影响因子：
2
作者：
Cooper, Nicola J.;Sutton, Alex J.;Welton, Nicky J.
通讯作者：
Welton, Nicky J.
影响因子：
3.2
作者：
Ji L;Onishi Y;Ahn CW;Agarwal P;Chou CW;Haber H;Guerrettaz K;Boardman MK
通讯作者：
Boardman MK
影响因子：
16.2
作者：
Davies M;Heller S;Sreenan S;Sapin H;Adetunji O;Tahbaz A;Vora J
通讯作者：
Vora J
影响因子：
5
作者：
Derosa, Giuseppe;Putignano, Pietro;Maffioli, Pamela
通讯作者：
Maffioli, Pamela